Skip to main content

Strengthening the evidence base to evaluate preventive interventions against respiratory syncytial virus (RSV)

  1. As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness o...

    Authors: Padmini Srikantiah and Keith P. Klugman
    Citation: BMC Medicine 2023 21:177
  2. Data on the economic burden of RSV-associated illness will inform decisions on the programmatic implementation of maternal vaccines and monoclonal antibodies. We estimated the cost of RSV-associated illness in...

    Authors: Jocelyn Moyes, Stefano Tempia, Sibongile Walaza, Meredith L. McMorrow, Florette Treurnicht, Nicole Wolter, Anne von Gottberg, Kathleen Kahn, Adam L. Cohen, Halima Dawood, Ebrahim Variava and Cheryl Cohen
    Citation: BMC Medicine 2023 21:146
  3. Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific bu...

    Authors: Jocelyn Moyes, Stefano Tempia, Sibongile Walaza, Meredith L. McMorrow, Florette Treurnicht, Nicole Wolter, Anne von Gottberg, Kathleen Kahn, Adam L. Cohen, Halima Dawood, Ebrahim Variava and Cheryl Cohen
    Citation: BMC Medicine 2023 21:139
  4. Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in young children. A number of mathematical models have been used to assess the cost-effectiveness of RSV prevention strategies, but ...

    Authors: Sarwat Mahmud, Ranju Baral, Colin Sanderson, Clint Pecenka, Mark Jit, You Li and Andrew Clark
    Citation: BMC Medicine 2023 21:138
  5. Respiratory syncytial virus (RSV) is among the leading childhood causes of viral pneumonia worldwide. Establishing RSV-associated morbidity and mortality is important in informing the development, delivery str...

    Authors: Bryan O. Nyawanda, Nickson Murunga, Nancy A. Otieno, Godfrey Bigogo, Joyce U. Nyiro, Elisabeth Vodicka, Marc Bulterys, D. James Nokes, Patrick K. Munywoki and Gideon O. Emukule
    Citation: BMC Medicine 2023 21:122
  6. Approximately 97% of global deaths due to RSV occur in low- and middle-income countries (LMICs). Until recently, the only licensed preventive intervention has been a shortacting monoclonal antibody (mAb), pali...

    Authors: Rachel Wittenauer, Clint Pecenka and Ranju Baral
    Citation: BMC Medicine 2023 21:121
  7. Respiratory syncytial virus (RSV) causes a substantial burden of acute lower respiratory infection in children under 5 years, particularly in low- and middle-income countries (LMICs). Maternal vaccine (MV) and...

    Authors: Mihaly Koltai, Jocelyn Moyes, Bryan Nyawanda, Joyce Nyiro, Patrick K. Munywoki, Stefano Tempia, Xiao Li, Marina Antillon, Joke Bilcke, Stefan Flasche, Philippe Beutels, D. James Nokes, Cheryl Cohen and Mark Jit
    Citation: BMC Medicine 2023 21:120
  8. Little information is available on the costs of respiratory syncytial virus (RSV) in Vietnam or other low- and middle-income countries. Our study estimated the costs of LRTIs associated with RSV infection amon...

    Authors: Lien Anh Ha Do, Elisabeth Vodicka, An Nguyen, Thi Ngoc Kim Le, Thi Thanh Hai Nguyen, Quang Tung Thai, Van Quang Pham, Thanh Uyen Pham, Thu Ngoc Nguyen, Kim Mulholland, Minh Thang Cao, Nguyen Thanh Nhan Le, Anh Tuan Tran and Clinton Pecenka
    Citation: BMC Infectious Diseases 2023 23:73

Guest edited by Mark Jit


Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants, with most of the disease burden in low- and middle-income countries. Several candidate vaccines and monoclonal antibodies against RSV are showing promise in clinical trials. In this collection, BMC Medicine and BMC Infectious Diseases present a series of articles that update the evidence base on the health and economic impact of paediatric RSV in low- and middle-income countries, as well as the cost-effectiveness of preventive interventions.

The collection includes new analyses of primary health and economic data in South Africa, Kenya and Vietnam, systematic reviews and cost-effectiveness analyses that use these new data to update our understanding of the value of pipeline prophylactic innovations. In particular, hospital data from South Africa and Kenya have been analysed at a more granular age breakdown than before. These show that interventions able to prevent RSV cases very early in life (such as maternal vaccination and monoclonal antibodies) may be more cost-effective than previously estimated. The implications of this evidence for policy and funding decisions are highlighted in an editorial by Keith Klugman and Padmini Srikantiah from the Bill & Melinda Gates Foundation.

The collection was developed by a consortium consisting of PATH, the National Institute for Communicable Diseases Of South Africa (NICD), the Kenya Medical Research Institute (KEMRI) – Wellcome Trust Research Programme, the London School of Hygiene & Tropical Medicine, the US Centres for Disease Control and Prevention and the University of Antwerp. The research and open access to all accepted articles was funded by the Bill & Melinda Gates Foundation.

All articles in the collection were peer reviewed, and the responsibility for all final editorial decisions on the content for this collection was with the Chief Editor.